The earnings call presented strong financial growth driven by key products, successful trial results, and significant investments in manufacturing. However, challenges remain with regulatory hurdles, potential tariff impacts, and market dynamics in the obesity segment. The balance of positive revenue growth and strategic investments against these challenges suggests a cautiously optimistic outlook.

Company Guidance -

Q2 2025

During the Q1 2025 earnings call, Eli Lilly & Company reported a robust financial performance with a 45% increase in revenue compared to Q1 2024, driven by key products like Mounjaro, Zepbound, and Verzenio. The company's gross margin was 83.5%, with marketing expenses increasing by 26% and R&D expenses by 8%. Lilly achieved several pipeline milestones, including the approval of Omvoh in the U.S., EU, and Japan. They also announced significant U.S. manufacturing investments exceeding $50 billion since 2020. Despite the impact of acquired IPR&D charges reducing earnings per share by $1.72, the company delivered an EPS of $3.34. Looking ahead, Lilly anticipates further clinical trial readouts for orforglipron and potential regulatory submissions for obesity treatments by year-end 2025, while maintaining a focus on expanding their product pipeline and manufacturing capabilities.

Strong Revenue Growth

Revenue grew 45% compared to Q1 of 2024, driven by key products like Mounjaro and Zepbound, which contributed over $4 billion in growth and accounted for $7.5 billion of the company's revenue.

Phase 3 Orforglipron Trial Success

Orforglipron achieved significant results in its Phase 3 trial for Type 2 diabetes, with hemoglobin A1c reductions of 1.3% to 1.6% and weight loss of approximately 16 pounds or 7.9% body weight at the highest dose.

Manufacturing Investment Expansion

Lilly announced over $50 billion in new U.S. manufacturing investments since 2020, including plans to build four new facilities, three of which will be active pharmaceutical ingredient facilities.

Strong Performance of Mounjaro and Zepbound

Mounjaro sales were $3.8 billion, more than double the same quarter last year, and Zepbound sales increased by $1.8 billion to $2.3 billion, making it the U.S. market leader in anti-obesity prescriptions.

Strong Financial Performance Metrics

Gross margin increased to 83.5% in Q1, and the non-GAAP performance margin was 42.6%, an increase of over 11 percentage points from Q1 2024.

Eli Lilly & Co (LLY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LLY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	5.60 / -	3.92	―	―	―
May 01, 2025	2025 (Q1)	3.26 / 3.34	2.58	29.46% (+0.76)
Feb 06, 2025	2024 (Q4)	5.04 / 5.32	2.49	113.65% (+2.83)
Oct 30, 2024	2024 (Q3)	1.42 / 1.18	0.1	1080.00% (+1.08)
Aug 08, 2024	2024 (Q2)	2.74 / 3.92	2.11	85.78% (+1.81)
Apr 30, 2024	2024 (Q1)	2.47 / 2.58	1.62	59.26% (+0.96)
Feb 06, 2024	2023 (Q4)	2.30 / 2.49	2.09	19.14% (+0.40)
Nov 02, 2023	2023 (Q3)	-0.18 / 0.10	1.98	-94.95% (-1.88)
Aug 08, 2023	2023 (Q2)	1.98 / 2.11	1.25	68.80% (+0.86)
Apr 27, 2023	2023 (Q1)	1.73 / 1.62	2.62	-38.17% (-1.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LLY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$897.11	$792.48	-11.66%
Feb 06, 2025	$839.01	$867.10	+3.35%
Oct 30, 2024	$898.69	$842.25	-6.28%
Aug 08, 2024	$766.89	$839.56	+9.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.